{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}],"title":"Cytogenetic response"},{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"78"}],"title":"No cytogenetic response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"Major erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \\> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.\n\nEvaluation of cytogenetic response requires 20 analyzable metaphases before and after treatment, which must be done on bone marrow only. Fluorescent in situ hybridization (FISH) may be used as a supplement to follow a specifically defined cytogenetic abnormality, but it is not a substitute for conventional cytogenetic studies. Cytogenetic response is defined as follows:\n\nComplete response: Restoration of a normal karyotype in patients with a documented pre-existing clonal (\\>2 metaphases abnormal) chromosome abnormalities.\n\nPartial response: \\> 50% reduction in the percentage of bone marrow metaphases with only clonal abnormality.","groups":[{"description":"Patients with major erythroid response","id":"OG000","title":"Major Erythroid Response"},{"description":"Patients without major erythroid response","id":"OG001","title":"No Major Erythroid Response"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable patients in both arms A and B who had both major erythroid response data and cytogenetic response data","reportingStatus":"POSTED","timeFrame":"Assessed at baseline and after completion of 16 weeks of treatment","title":"Association Between Major Erythroid Response and Cytogenetic Response","type":"SECONDARY","unitOfMeasure":"Participants"}